EpiCast Report: Meningococcal Disease – Epidemiology Forecast to 2025
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Invasive meningococcal disease (IMD) is a life-threatening condition caused by the bacterium Neisseria meningitidis (N. meningitidis), an encapsulated gram-negative diplococcus that is a pathogen exclusive to humans. N. meningitidis is carried harmlessly in the nasopharynx of approximately 5?11% of adults and up to 25% of adolescents. Life-threatening disease occurs when the bacterium invades body tissue, which most commonly manifests as meningitis or septicemia. The disease is transmitted via respiratory droplets, through close or prolonged contact with an infected individual. N. meningitidis is classified into 13 distinct serogroups; however, almost all invasive disease in humans is a result of infection with one of 6 serogroups.
In the 8MM, GlobalData epidemiologists forecast that the laboratory-confirmed incident cases of IMD will decrease from 4,153 cases in 2015 to 3,169 cases in 2025 at an Annual Growth Rate (AGR) of negative 2.37%. Brazil had the highest number of laboratory-confirmed incident cases of IMD among the individual markets of the 8MM throughout the forecast period. The 5EU combined will account for 45.32% of laboratory-confirmed incident cases in 2015, and by 2025 this is forecast to increase to 59.58%. In the 8MM in 2015, 43.37% of the laboratory-confirmed incident cases of IMD are serogroup C disease, 36.46% are serogroup B disease, 5.25% are serogroup Y disease, and 14.98% are disease caused by other serogroups combined. GlobalData epidemiologists estimated that in the 8MM in 2015, 10.86% of laboratory-confirmed incident cases of IMD would occur in the population less than 1 year of age.
Scope
The Meningococcal disease (IMD) EpiCast Report and EpiCast Model provide an overview of the risk factors, comorbidities, and the global and historical trends for IMD in eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Brazil). For the US, 5EU (France, Germany, Italy, Spain, and UK), and Brazil, it includes a 10-year epidemiological forecast for laboratory-confirmed incident cases of all IMD (all serogroups combined), segmented by sex and age (in age groups of <1 year and 1–4 years, then in 10 year age groups to =65 years), and laboratory-confirmed incident cases of serogroup B, serogroup C, serogroup Y, and all other IMD combined. For Japan, it includes a 10-year epidemiological forecast for laboratory-confirmed incident cases of IMD segmented by sex and age (<1 year and =1 year); and a 10-year epidemiological forecast for laboratory-confirmed incident cases of specific serogroups. For the US, this report also provides a 10-year forecast of the number of first-year college students and the number of first-year college students living in campus accommodation.
The IMD epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Infectious Disease reports